• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia's earnings

    8/27/25 8:55:00 AM ET
    $ABT
    $ICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $ABT alert in real time by email

    NEW YORK, Aug. 27, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. 

    Ashley Mastronardi delivers the pre-market update on August 27th

    • Equities are up this morning as investors wait for chip giant Nvidia's Q2 earnings report. The company is set to release the earnings after market close this afternoon.
    • As the most heavily weighted company in the S&P 500 at more than 8%, Nvidia's results will likely be felt by investors throughout the rest of the week and provide insight into the level of demand for AI.
    • The major averages are coming off a day of fractional gains with investors shaking off President Trump's move to fire Fed Governor Lisa Cook ahead of the Fed's next policy meeting in Mid-September.

    Opening Bell

    Abbott (NYSE:ABT) and the Big Ten Conference are teaming up to address the worst blood shortage in a generation

    Closing Bell

    Van Eck celebrates the 70th anniversary of Van Eck and its first ETF listing

    Click here to download the NYSE TV App

    NYSE Logo (PRNewsfoto/New York Stock Exchange)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-content-advisory-pre-market-update--wall-street-braces-for-nvidias-earnings-302539974.html

    SOURCE New York Stock Exchange

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $ICE

    CompanyDatePrice TargetRatingAnalyst
    Intercontinental Exchange Inc.
    $ICE
    10/13/2025$210.00Outperform → Strong Buy
    Raymond James
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Intercontinental Exchange Inc.
    $ICE
    10/14/2024$185.00Strong Buy → Outperform
    Raymond James
    Abbott Laboratories
    $ABT
    10/8/2024$130.00Outperform
    Oppenheimer
    Intercontinental Exchange Inc.
    $ICE
    9/27/2024$200.00Outperform
    RBC Capital Mkts
    Intercontinental Exchange Inc.
    $ICE
    9/26/2024$182.00Buy
    TD Cowen
    More analyst ratings

    $ABT
    $ICE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $ICE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Advisory: Pre-Market Update + U.S. Economy Adds 119,000 Jobs in September

    NEW YORK, Nov. 21, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on November 21st Wall Street is starting the day in positive territory following a choppy session yesterday. Major indexes struggled as investors weighed tech valuations and economic data, setting the stage for a cautious rebound this morning.NVIDIA surged early on Thursday, only to reverse course mid-day and close in the red. The S&P 500, where NVIDIA holds the largest weight, fell more

    11/21/25 8:55:00 AM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    NYSE Content Advisory: Pre-Market update + BLS Reveals First Look at Labor Market Since September

    NEW YORK, Nov. 20, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on November 20th Stocks are higher Thursday morning as investors react to a wave of reports, including strong earnings from NVIDIA that lifted the S&P 500 and Dow.Fresh September jobs data showed the U.S. added about 50,000 positions, while the BLS confirmed the October report won't be released due to the government shutdown.Fed minutes revealed division over the recent rate cut, with tr

    11/20/25 8:55:00 AM ET
    $EMR
    $ICE
    Consumer Electronics/Appliances
    Technology
    Investment Bankers/Brokers/Service
    Finance

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $ABT
    $ICE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intercontinental Exchange upgraded by Raymond James with a new price target

    Raymond James upgraded Intercontinental Exchange from Outperform to Strong Buy and set a new price target of $210.00

    10/13/25 8:40:25 AM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $ICE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Surdykowski Andrew J exercised 1,770 shares at a strike of $50.01 and sold $269,960 worth of shares (1,770 units at $152.52) (SEC Form 4)

    4 - Intercontinental Exchange, Inc. (0001571949) (Issuer)

    11/21/25 4:35:03 PM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    Chief Executive Officer Sprecher Jeffrey C gifted 46,000 shares and sold $22,962,583 worth of shares (150,000 units at $153.08), decreasing direct ownership by 4% to 1,116,991 units (SEC Form 4)

    4 - Intercontinental Exchange, Inc. (0001571949) (Issuer)

    11/21/25 4:30:16 PM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    General Counsel Surdykowski Andrew J sold $314,231 worth of shares (2,081 units at $151.00), decreasing direct ownership by 4% to 44,212 units (SEC Form 4)

    4 - Intercontinental Exchange, Inc. (0001571949) (Issuer)

    11/13/25 4:30:10 PM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    $ABT
    $ICE
    SEC Filings

    View All

    Abbott Laboratories filed SEC Form 8-K: Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    11/21/25 4:06:09 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Intercontinental Exchange Inc.

    144 - Intercontinental Exchange, Inc. (0001571949) (Subject)

    11/20/25 4:23:24 PM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    11/20/25 7:37:40 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $ICE
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lord Hill of Oareford Elected to Board of Directors of Intercontinental Exchange

    Intercontinental Exchange, Inc. (NYSE:ICE), a leading global provider of technology and data, today announced that its Board of Directors has elected The Rt. Hon. the Lord Hill of Oareford CBE (Lord Hill) as a new director, effective September 18, 2025. Lord Hill, who currently serves on the Board of Directors of ICE Endex Markets, a subsidiary of ICE, is also expected to join the Board of Directors of ICE Futures Europe subject to regulatory approval. "On behalf of the Board, I am pleased to welcome our colleague, Lord Hill, to his expanded role at ICE," said Jeffrey C. Sprecher, Founder, Chair and CEO of Intercontinental Exchange. "Lord Hill brings tremendous depth and breadth of experi

    9/18/25 4:15:00 PM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    NYSE Content Advisory: Pre-Market update + Fed Chair Jerome Powell Set to Deliver Jackson Hole Speech

    NEW YORK, Aug. 22, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on August 22nd Markets are closely watching the Fed's economic policy symposium in Jackson Hole, where Chair Jerome Powell will speak at 10 a.m. ET.Nearly 70% of traders expect a Fed rate cut in September amid dual concerns about inflation and employment highlighted in the Fed's July meeting minutes.The Fed's July meeting minutes emphasized policymakers' concerns about both inflation ris

    8/22/25 8:55:00 AM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    $ABT
    $ICE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Intercontinental Exchange Inc. (Amendment)

    SC 13G/A - Intercontinental Exchange, Inc. (0001571949) (Subject)

    2/13/24 1:23:13 PM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $ICE
    Financials

    Live finance-specific insights

    View All

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Intercontinental Exchange Approves Fourth Quarter Dividend of $0.48 per Share

    Intercontinental Exchange (NYSE:ICE), a leading global provider of technology and data, announced today a $0.48 per share dividend for the fourth quarter of 2025, which is up 7% from the $0.45 per share dividend paid in the fourth quarter of 2024. The cash dividend is payable on December 31, 2025 to stockholders of record as of December 16, 2025. The ex-dividend date is December 16, 2025. About Intercontinental Exchange Intercontinental Exchange, Inc. (NYSE:ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-c

    10/30/25 7:35:00 AM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance

    Intercontinental Exchange Reports Strong Third Quarter 2025

    Intercontinental Exchange (NYSE:ICE): 3Q25 net revenues of $2.4 billion, +3% y/y   3Q25 GAAP diluted earnings per share (EPS) of $1.42, +25% y/y   3Q25 adj. diluted EPS of $1.71, +10% y/y   3Q25 operating income of $1.2 billion, +6% y/y; adj. operating income of $1.4 billion, +3% y/y   3Q25 operating margin of 49%; adj. operating margin of 59%   Through September 30, 2025, returned over $1.7 billion to stockholders, including $894 million in share repurchases   Jeffrey C. Sprecher,ICE Chair & Chief Executive Officer, said,"We are pleased to report our third quarter results, which extend our track record of revenue and earnings per

    10/30/25 7:30:00 AM ET
    $ICE
    Investment Bankers/Brokers/Service
    Finance